alpha-synuclein — LLMpedia

alpha-synuclein
Name	Alpha-synuclein
Gene	SNCA
Organism	Homo sapiens
Length	~140 amino acids
Localization	Cytosol, synaptic terminals, nucleus, mitochondria
Function	Presynaptic regulation, vesicle trafficking

Contents

alpha-synuclein is a small neuronal protein implicated in synaptic regulation and neurodegenerative diseases. Initially identified in studies of avian brain and later in human Substantia Nigra tissue, it became central to research in Parkinson's disease, Dementia with Lewy bodies, and other synucleinopathies. Investigations by teams at institutions such as Massachusetts Institute of Technology, Stanford University, University of Cambridge, and National Institutes of Health have elucidated its role in physiology and pathology.

Structure and biochemical properties

Alpha-synuclein is intrinsically disordered in solution, composed of an N-terminal amphipathic region, a hydrophobic non-amyloid-β component (NAC) core, and an acidic C-terminal tail. Structural studies using methods from groups at European Molecular Biology Laboratory, Max Planck Institute, Cold Spring Harbor Laboratory, and California Institute of Technology employed nuclear magnetic resonance, cryo-electron microscopy, and X-ray techniques to resolve conformations. Biochemical analyses by laboratories at Harvard University, Columbia University, University of California, San Francisco, and Johns Hopkins University characterized oligomerization, monomer–membrane interactions, and metal binding. Interactions with phospholipids, cholesterol, and synaptic vesicle proteins were reported in collaborations linked to Yale University, University College London, University of Oxford, and McGill University.

Alpha-synuclein concentrates at presynaptic terminals and associates with synaptic vesicles, implicated in neurotransmitter release, vesicle recycling, and SNARE complex modulation. Functional studies from teams at University of Pennsylvania, Cold Spring Harbor Laboratory, Massachusetts General Hospital, and Princeton University linked it to synaptic plasticity, dopamine release in pathways involving Ventral Tegmental Area and Substantia Nigra, and interactions with proteins such as Synapsin I, VAMP2, and Complexin. Localization to the nucleus and mitochondria was reported in studies from Scripps Research Institute, Karolinska Institute, Riken, and Weizmann Institute of Science, noting impacts on transcriptional regulation and mitochondrial dynamics. Physiological roles have been contrasted across model organisms used by groups at University of Tokyo, University of Zurich, University of Barcelona, and Australian National University.

Pathological aggregation proceeds from soluble monomers to oligomers, protofibrils, and amyloid fibrils; kinetics and morphology vary with environment, mutations, and seeding. Foundational aggregation kinetics work was performed at Princeton University, ETH Zurich, Institute Pasteur, and University of Geneva. Cryo-EM structures revealing distinct fibril folds were described by teams at Max Planck Institute for Biophysical Chemistry, MRC Laboratory of Molecular Biology, University of Basel, and Rockefeller University. The concept of distinct “strains” with varying seeding properties and neurotropism emerged from research groups at Duke University, University of California, San Diego, McMaster University, and Mount Sinai Hospital. Biophysical modulation by metals, pH, lipids, and post-translational modifications was characterized in studies at Purdue University, University of Illinois Urbana-Champaign, University of Copenhagen, and University of Toronto.

Accumulation of aggregated alpha-synuclein correlates with neuronal dysfunction and cell death in Parkinson's disease, Multiple System Atrophy, and Dementia with Lewy bodies. Neuropathological mapping by teams at Mayo Clinic, University College London Hospitals, Karolinska University Hospital, and University of California, Los Angeles documented Lewy bodies and glial cytoplasmic inclusions. Proposed mechanisms include synaptic failure, mitochondrial impairment, endoplasmic reticulum stress, lysosomal dysfunction, and neuroinflammation; investigators from Imperial College London, University of Sydney, University of Toronto Scarborough, and University of Florida contributed evidence linking these processes to disease progression. Cell-to-cell propagation akin to prion-like spread was advanced by studies at Istituto Superiore di Sanità, University of Pennsylvania Perelman School of Medicine, Weill Cornell Medicine, and Northwestern University.

SNCA gene multiplications, point mutations, and regulatory variants were identified in familial Parkinsonism by research consortia at National Institute of Neurological Disorders and Stroke, Michael J. Fox Foundation, Genentech, and academic groups at University of Edinburgh, University of Pittsburgh, and University of Helsinki. Pathogenic missense mutations (e.g., A53T, E46K, A30P) and gene dosage effects alter aggregation propensity. Post-translational modifications—phosphorylation, ubiquitination, acetylation, nitration, and truncation—modulate structure and toxicity; proteomic surveys were performed by teams at Broad Institute, European Bioinformatics Institute, Proteomics Initiative at NIH, and Fred Hutchinson Cancer Research Center. Lysosomal pathway genes such as GBA and regulators like LRRK2 and PINK1 were linked genetically and biochemically in consortia including International Parkinson and Movement Disorder Society.

Model systems span yeast, Caenorhabditis elegans, Drosophila, zebrafish, rodent transgenic and viral models, and patient-derived induced pluripotent stem cells developed at centers including Cold Spring Harbor Laboratory, University of Oxford, University of Basel, National Taiwan University Hospital, and Stanford Neurosciences Institute. In vitro assays use recombinant protein, seeded polymerization, Thioflavin assays, and single-molecule fluorescence implemented at MIT Koch Institute, Salk Institute, University of Michigan, and University of Washington. Advanced imaging and longitudinal tracking employed platforms at European Synchrotron Radiation Facility, Argonne National Laboratory, Max Planck Society, and National Center for Microscopy and Imaging Research.

Therapeutic approaches under investigation include immunotherapy, small-molecule aggregation inhibitors, antisense oligonucleotides, gene therapy, chaperone modulators, and cell-replacement strategies pursued by biotech and academic collaborators such as Biogen, Roche, AbbVie, Novartis, AstraZeneca, Celgene, Alnylam Pharmaceuticals, and institutions like Massachusetts General Hospital and Karolinska Institutet. Biomarker efforts—CSF, blood, PET ligands, and seed amplification assays—are coordinated by consortia including Parkinson's Progression Markers Initiative, Alzheimer's Disease Neuroimaging Initiative, European Parkinson's Disease Association, and clinical centers at Johns Hopkins Medicine, Cleveland Clinic, and UCLA Health. Clinical trials and regulatory interactions involve Food and Drug Administration, European Medicines Agency, and patient advocacy groups such as Parkinson's Foundation and Michael J. Fox Foundation.

Category:Proteins